Pharma stock jumps 3% after signing supply agreement with Beihai BiotechPharma stock jumps 3% after signing supply agreement with Beihai Biotech

Introduction:

Leading pharma company enters into an exclusive licensing, supply, and commercialization agreement with Beihai Biotech for BEIZRAY, a product aimed at treating various cancers in the US market, following FDA approval for the innovative formulation.

Also Read: Chemical stock jumps after it signs technology transfer agreement with Ningxia Jinhua

Share price movement of Zydus Lifesciences:

On February 17, 2025, Zydus Lifesciences Ltd opened at ₹903.60, up 0.22% from its previous close of ₹901.60. The stock hit a high of ₹927.70 (2.89%) and a low of ₹894.80. By 3:18 PM, it traded at ₹924.10, rising 2.50%, with a market cap of ₹92,986.08 crore.

Zydus Partners with Beihai Biotech for BEIZRAY:

Zydus Lifesciences Ltd. announced a strategic partnership with Zhuhai Beihai Biotech Co., Ltd. through its subsidiary, Zydus Lifesciences Global FZE. The collaboration involves the exclusive licensing, supply, and commercialization of BEIZRAY (Albumin Solubilized Docetaxel Injection) for the US market.

Under the terms of the agreement, Beihai Biotech will be responsible for manufacturing and supplying BEIZRAY, while Zydus will manage the product’s commercialization in the United States. Beihai Biotech will receive upfront payments, milestone payments based on sales targets, and a share of BEIZRAY’s net profits in the US.

Also Read: How to Trade Like a Pro: 3 Technical Analysis Tools Used by Traders

BEIZRAY is an innovative formulation of Docetaxel, free from synthetic excipients like Polysorbate-80. Approved by the US FDA in October 2024, BEIZRAY is used in the treatment of various cancers, including breast, lung, prostate, gastric, and head and neck cancer.

Recent news on Zydus Lifesciences:

As of January 07, 2025, Zydus Lifesciences Ltd announced an agreement with CVS Caremark to add Zituvio, Zituvimet, and Zituvimet XR tablets to its template formulary. This inclusion, effective January 1, 2025, expands access for diabetes treatment.

Stock performance of Zydus Lifesciences for Period of 1 week, 6 months and 1 year:

Zydus Lifesciences Ltd has seen a decline of 6.51% over the past week and 25.2% over the last six months. However, the company has achieved a positive return of 1.12% over the past year, indicating some resilience.

Also Read: PSU stock jumps after signing MoU with National Sugar Institute for bioethanol production

Shareholding pattern of Zydus Lifesciences:

Particulars	Dec 2024	Sep 2024	Jun 2024
Promoter	75.00%	75.00%	75.00%
FII	7.50%	7.50%	5.60%
DII	10.70%	10.60%	12.60%
Public	6.90%	6.90%	6.80%

About Zydus Lifesciences:

Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE) is a global leader in healthcare, focusing on innovative therapies, including cancer treatments. With over 27,000 employees, it is committed to delivering quality healthcare solutions that improve lives worldwide.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.